• 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

알레르기 비염의 침 치료에 대한 경제성 평가 연구 경향 분석

A Review of Economic Evaluations in Acupuncture for Allergic Rhinitis


Objective : The purpose of this study is to analyze research trends on the cost-effectiveness in acupuncture for patients with allergic rhinitis. Methods : The literature and research in allergic rhinitis was searched in electronic databases, such as National Health Service Economic Evaluation Database(NHS EED) and the Cochrane Database of Systematic Reviews(CDSR). The general characteristics and the results of each economic analysis such as incremental cost-effectiveness ratios(ICERs) were extracted. Results : In total, thirty seven studies were searched, and two studies were analyzed. They were cost-utility analysis(CUA)s that measured quality-adjusted life years(QALYs). One study showed that the ICER was €22,798 per QALY and was robust in sensitivity analysis. Another showed that the ICER was between €31,241 and €118,889 from society's perspective and between €20,807 and €74,585 from a third-party payer's perspective. Conclusions : Any generalization of these results needs to be made with caution given the specific effects of acupuncture and the difference of cost data in the various countries. Further studies are needed on this topic in order to demonstrate the cost-effectiveness clearly.

저자의 다른 논문

참고문헌 (27)

  1. Kim CW. Current Clinical Practice : Current Update on Allergic Rhinitis. Korean J of Internal Medicine. 2012;82(3):298-303. 
  2. Ng ML, Warlow RS, Chrishanthan N, Ellis C, Walls R. Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (I). Clin Exp Allergy. 2000;30: 1314-31. 
  3. Korea National Health Insurance Service and Korea Health Insurance Review and Assessment Services. National Health Insurance Statistical Annual Report. 2014. 
  4. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Safe. 2003;26:863–93. 
  5. Krouse JH, Krouse HJ. Patient use of traditional and complementary therapies in treating rhinosinusitis before consulting an otolaryngologist. Laryngoscope. 1999;109(8):1223–7. 
  6. Scha¨fer T, Riehle A, Wichmann HE, Ring J. Alternative medicine in allergies—revalence, patterns of use, and costs. Allergy. 2002;57(8):694–700. 
  7. Xue CC, An X, Cheung TP, Da Costa C, Lenon GB, Thien FC, et al. Acupuncture for persistent allergic rhinitis: a randomised, sham-controlled trial. Med J Aust. 2007;187(6):337–41. 
  8. Choi SM, Park JE, Li SS, Jung H, Zi M, Kim TH, et al. A multicenter, randomized, controlled trial testing the effects of acupuncture on allergic rhinitis. Allergy. 2013 Mar;68(3):365-74. 
  9. Kim CM. Health Economics and Outcomes Research. Korean J Fam Med. 2009;30:577-87. 
  10. Herman PM, Poindexter BL, Witt CM, Eisenberg DM. Are complementary therapies and integrative care cost-effective? A systematic review of economic evaluations. BMJ Open. 2012 Sep;3:2(5). 
  11. Park BJ. Evidence-based Healthcare. 2009. 
  12. Drummond FM, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford. 2015. 
  13. Witt CM, Reinhold T, Jena S, Brinkhaus B, Willich SN. Cost-effectiveness of acupuncture in women and men with allergic rhinitis: a randomized controlled study in usual care. Am J Epidemiol. 2009 Mar 1;169(5):562-71. 
  14. Reinhold T, Roll S, Willich SN, Ortiz M, Witt CM, Brinkhaus B. Cost-effectiveness for acupuncture in seasonal allergic rhinitis: economic results of the ACUSAR trial. Ann Allergy Asthma Immunol. 2013 Jul;111(1):56-63. 
  15. Health Insurance Review Agency. Guidelines for Economic Evaluation of Pharmaceuticals in Korea. 2006. 
  16. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246-52. 
  17. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990–1997. JAMA. 1998;280:1569–75. 
  18. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Advance data from Vital and Health Statistics. Hyattsville, MA: National Center for Health Statistics. 2004. 
  19. Nahin RL, Barnes PM, Stussman BJ, Bloom B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. National Health Statistics Reports. Hyattsville, MA: National Center for Health Statistics. 2009. 
  20. Doran CM, Chang DH, Kiat H, Bensoussan A. Review of economic methods used in complementary medicine. J Altern Complement Med. 2010;16:591–5. 
  21. Kennedy DA, Hart J, Seely D. Cost-effectiveness of natural health products: a systematic review of randomized clinical trials. Evid-Based Complement Altern Med. 2009;6:297–304. 
  22. Jang BH, Choi IH, Kim KS, Kim HT, Kim KJ, Kim MH, et al. Current status of allergic rhinitis patients in Korean Medicine hospitals - Exploratory study based on electronic medical records of 3 hospitals. J Korean Med Ophthalmol Otolaryngol Dermatol. 2014;27(1):117-29. 
  23. Pang F. Design, analysis and presentation of multinational economic studies: the need for guidance. Pharmacoeconomics. 2002;20(2):75-90. 
  24. National Institute for Clinical Excellence. Guidance for Manufacturers and Sponsors. Technology Appraisals Process Series5. NICE; 2001.6. 
  25. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D. Quality of life measures in health care Ⅱ: design, analysis, and interpretation. BMJ. 1992;305(7):1145-8. 
  26. Canadian Coordination Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals. Ottawa:CCOHTA. 1997.11. 
  27. O’Brien BJ. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. American Journal of Managed Care. 1997;3 Suppl:S33-9. 

이 논문을 인용한 문헌 (0)

  1. 이 논문을 인용한 문헌 없음

DOI 인용 스타일

"" 핵심어 질의응답